INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

• ClinicalTrials.gov Identifier: NCT02386826
• Recruitment Status: Active, not recruiting
• First Posted: March 12, 2015
• Last Update Posted: November 2, 2022
• Sponsor: SCRI Development Innovations, LLC
• Collaborator: Novartis
• Information provided by (Responsible Party): SCRI Development Innovations, LLC

Study Description

Brief Summary:

The purpose of this study is to determine whether the combination of two agents, INC280 and bevacizumab, is safe and effective when administered to patients with Glioblastoma Multiforme (GBM) who have progressed after receiving prior therapy or who have unresectable GBM.

Condition or disease	Intervention/treatment	Phase
Glioblastoma Multiforme; Gliosarcoma; Colorectal Cancer; Renal Cell Carcinoma	Drug: INC280; Biological: bevacizumab	Phase 1

Detailed Description:

Despite recent advances, glioblastoma multiforme (GBM) remains an incurable malignancy with a short expected survival. c-MET signalling promotes invasive growth and has been described in various cancers. INC280 is a highly potent and selective c-MET inhibitor which also penetrates the blood-brain barrier. In this open-label, multicenter Phase 1b study, investigators determined the optimal dose of the INC280/bevacizumab combination to administer to patients. Enrollment has now expanded in order to treat 3 cohorts of GBM patients: those who progressed after ≥ first-line standard therapy, those who progressed after ≥ second-line therapy with INC280/bevacizumab, and those with unresectable GBM.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 65 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase Ib Study Evaluating the c-Met Inhibitor INC280 in Combination With Bevacizumab in Patients With Glioblastoma Multiforme (GBM)
• Actual Study Start Date: September 22, 2015
• Actual Primary Completion Date: July 31, 2021
• Estimated Study Completion Date: June 2023

Arms and Interventions

Arm

Intervention/treatment

Experimental: INC280 + Bevacizumab; Dose Escalation: 18 GBM patients received bevacizumab 10 mg/kg intravenously (IV) once every 2 weeks in combination with INC280 given by mouth (PO) starting at 100 mg twice daily and escalating on a 3+3 escalation pattern until the maximum tolerated dose (MTD) was determined.; Dose Expansion: Up to 45 GBM patients enrolled in 3 Cohorts: Cohort A: 20 GBM patients - progressed during or after standard 1st-line therapy; Cohort B: 15 GBM patients - progressed during or after 2nd-line bevacizumab therapy; Cohort C: 10 unresectable GBM patients. INC280: PO twice daily at the MTD. Bevacizumab: 10 mg/kg IV once every 2 weeks for Cohorts A and B; 15 mg/kg IV every 4 weeks for Cohort C Treatment cycles will be repeated every 28 days (4 weeks).

Drug: INC280; Dose Escalation: INC280 by mouth (PO) twice daily for 28 days according to the following schedule until the maximum tolerated dose (MTD) is determined: Dose Level 1 (starting dose): 200 mg (divided dose of 100 mg twice per day) Dose Level 2: 400 mg (divided dose of 200 mg twice per day) Dose Level 3: 800 mg (divided dose of 400 mg twice per day) Dose Expansion: INC280 PO twice daily at the MTD determined in the dose escalation phase; Other Name: INCB28060; Biological: bevacizumab; bevacizumab: 10 mg/kg IV every 2 weeks. Patients with unresectable GBM will be given 15 mg/kg IV every 4 weeks.; Other Name: Avastin

Outcome Measures

Primary Outcome Measures :

1. Maximum Tolerated Dose (MTD) of INC280 [ Time Frame: weekly for 4 weeks ]
   The MTD of INC280 to be administered with standard dose bevacizumab is determined as the highest dose at which ≤1 of 6 patients experiences a dose limiting toxicity (DLT) during one cycle (28 days) of therapy, assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v. 4.0.3

Secondary Outcome Measures :

1. Progression-free Survival [ Time Frame: every 8 weeks until treatment discontinuation, expected average of 6 months ]
   Progression-free survival is measured from Day 1 of study drug administration to disease progression or death on study. Disease progression is assessed by Response Assessment in Neuro-Oncology (RANO) criteria.
2. Overall Response Rate [ Time Frame: Every 8 weeks up to 6 months ]
   Defined as the proportion of patients with confirmed complete response or partial response (CR or PR) assessed according to RANO criteria. CR=complete disappearance of all measurable and non-measurable disease sustained for at least 4 weeks. PR=≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for at least 4 weeks.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

KEY POINTS:

1. Dose Escalation Phase: Histologic diagnosis of GBM or gliosarcoma. Progressed during or after standard 1st-line therapy for GBM. Patients scheduled to undergo a repeat primary surgical resection are also eligible. Measurable disease as measured by RANO (Response Assessment in Neuro-Oncology) criteria.

2. Dose Expansion Phase:

   Cohort A: Histologic diagnosis of GBM. Patients should have progressed during or after standard 1st-line therapy. Patients scheduled to undergo a repeat primary surgical resection are also eligible. Measurable disease as measured by RANO criteria.

   At least 5 patients must have an alteration of MET [as assessed by fluorescence in situ hybridization (FISH) (c-MET/centromere ratio ≥2, or c-MET gene copy number ≥ 5) or RT-PCR or Met immunohistochemistry (IHC) score of 2-3+ or a mutation].

   Cohort B: Histologic diagnosis of GBM patients who have progressed during or after 2nd-line therapy with bevacizumab or a bevacizumab-based regimen. Measurable disease according to RANO criteria.

   Cohort C: Histologic diagnosis of GBM by stereotactic biopsy in patients with unresectable brain tumors.

3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2 or Karnofsky Performance Scale (KPS) of at least 70%.
4. Adequate hematologic, renal and liver function
5. Life expectancy ≥ 3 months
6. Availability of archived tumor samples and/or willingness to provide tissue samples if resection is done. (Fresh tissue biopsy is not required if archival tissue is not available.)

Exclusion Criteria:

1. Prior treatment with bevacizumab for GBM patients eligible for Cohorts A and C. (Prior treatment with bevacizumab is permitted for GBM patients eligible for Cohort B only.)
2. Most recent chemotherapy ≤ 21 days to the start of treatment and ≥ Grade 2 chemotherapy-related side effects with the exception of alopecia.
3. Use of any investigational drug ≤ 21 days to the start of treatment or 5 half-lives (whichever is shorter) prior to the first dose of INC280 with bevacizumab. For study drugs for which 5 half-lives is ≤ 21 days, a minimum of 10 days between termination of the study drug and the start of treatment is required.
4. Uncontrolled seizures (Patients with a history of seizures are eligible if they are currently without seizures on a stable dose of anti-epileptic drugs for 14 days prior to enrollment.)
5. History of uncontrolled hereditary or acquired bleeding or thrombotic disorders.
6. Major surgery ≤ 28 days to the start of treatment, or subcutaneous venous access device placement ≤ 7 days to the start of treatment
7. A serious non healing wound, ulcer, or bone fracture ≤ 28 days to the start of treatment
8. Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered ≤ 28 days or limited field radiation for palliation ≤ 7 days prior to starting study drug or has not recovered from side effects of such therapy.
9. Leptomeningeal metastases or spinal cord compression due to disease.
10. Women of child-bearing potential.
11. Receiving drugs known to be strong inhibitors or inducers of CYP3A4 and cannot be discontinued 7 days prior to the start of INC280 treatment and during the course of the study, or medications that are known CYP3A4, CYP1A2, CYP2C8, CYP2C9 or CYP2C19 substrates with narrow therapeutic index, and cannot be discontinued during the course of the study.
12. Treatment with proton pump inhibitors within three days prior to study entry.
13. Cardiac disease currently or less than 6 months from baseline screening
14. Inadequately controlled hypertension (i.e., systolic blood pressure [SBP] >180 mmHg or diastolic blood pressure (DBP) >100 mmHg) (patients with values above these levels must have their blood pressure (BP) controlled with medication prior to starting treatment).
15. Currently receiving treatment with therapeutic doses of warfarin sodium. Low molecular weight heparin is allowed.

Contacts and Locations

Locations

United States, Colorado

Sarah Cannon Research Institute at HealthONE

Denver, Colorado, United States, 80218

United States, Connecticut

Yale School of Medicine

New Haven, Connecticut, United States, 06520

United States, Missouri

HCA Midwest - Kansas City

Kansas City, Missouri, United States, 64132

United States, Oklahoma

Oklahoma University Health Science Center

Oklahoma City, Oklahoma, United States, 73104

United States, Tennessee

Tennessee Oncology PLLC

Nashville, Tennessee, United States, 37203

Sponsors and Collaborators

SCRI Development Innovations, LLC

Novartis

Investigators

• Study Chair: Kent C. Shih, M.D.; SCRI Development Innovations, LLC

More Information

• Responsible Party: SCRI Development Innovations, LLC
• ClinicalTrials.gov Identifier: NCT02386826
• Other Study ID Numbers: SCRI REFMAL 365
• First Posted: March 12, 2015
• Last Update Posted: November 2, 2022
• Last Verified: November 2022

Keywords provided by SCRI Development Innovations, LLC:

INC280; c-MET Inhibitors; bevacizumab; Avastin; C-Met proto-oncogene

Additional relevant MeSH terms:

Glioblastoma; Carcinoma, Renal Cell; Gliosarcoma; Neoplasms by Site; Neoplasms; Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Adenocarcinoma; Carcinoma; Kidney Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Kidney Diseases; Urologic Diseases; Male Urogenital Diseases; Bevacizumab; Antineoplastic Agents, Immunological; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances